ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. [electronic resource]
Producer: 20120612Description: 367-78.e2 p. digitalISSN:- 1873-2399
- Antigens, CD34 -- analysis
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Apoptosis Regulatory Proteins -- physiology
- Bcl-2-Like Protein 11
- Benzamides
- Biphenyl Compounds -- pharmacology
- Cell Line, Tumor -- drug effects
- Down-Regulation -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Drug Screening Assays, Antitumor
- Drug Synergism
- Gene Expression Regulation, Leukemic -- drug effects
- Hematopoietic Stem Cells -- drug effects
- High-Temperature Requirement A Serine Peptidase 2
- Humans
- Imatinib Mesylate
- K562 Cells -- drug effects
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- pathology
- Membrane Proteins -- physiology
- Mitochondrial Proteins -- physiology
- Neoplasm Proteins -- biosynthesis
- Neoplastic Stem Cells -- drug effects
- Nitrophenols -- pharmacology
- Piperazines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins -- physiology
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Pyrimidines -- pharmacology
- Serine Endopeptidases -- physiology
- Sulfonamides -- pharmacology
- X-Linked Inhibitor of Apoptosis Protein -- biosynthesis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.